Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Aidan Fry
Data presented in The Lancet medical journal suggests a polypill fixed-dose combination of aspirin, atorvastatin and hydrochlorothiazide with either enalapril or valsartan could reduce the risk of cardiovascular events significantly.
With a constitutional challenge still pending in Germany, and lingering uncertainties over Brexit, Germany's federal government appears to have little idea when a planned European Unified Patent Court could come into effect.
The head of the UK’s health technology assessment body NICE is stepping down, while the country’s medicines agency, the MHRA, will have an interim chief in the run-up to the UK’s planned Brexit from the European Union on 31 October.
Greater clarity in reviewers’ comments and limiting the effect of originators’ label changes on pending applications would help improve the rate of generic applications approved by the FDA on the first review cycle, a US government report proposes.
With permission to export bulk drugs from China to the US expected soon, Siegfried is also making strides on offering services for filling biological drugs.
By licensing Covis’ Alvesco ciclesonide inhaler in central and eastern Europe, as well as preparing to launch thee Qysmia weight-loss brand for which it just obtained approval in Korea, Alvogen is expanding its portfolio of branded drugs.